Objective: The aims of this study were to examine executive dysfunction using an antisaccade (AS) task in normal elderly (NE) and patients with mild cognitive impairment (MCI) and Alzheimer disease (AD) as well as to evaluate the relationship between AS performance and cortical thinning within AD-associated regions.
Normal aging results in cognitive changes that frequently fall within the realm of executive function (EF) 1 and may indicate an increased risk of neurodegenerative disease. Precise measurements that illuminate mechanisms of EF changes find use as new tools for assessing cognitive decline.
One candidate measurement is the antisaccade (AS) task, a test of inhibitory control. Performance on this task is strongly correlated with neuropsychological tests of EF in multiple diseases, including schizophrenia [2] [3] [4] and dementias such as Alzheimer disease (AD) and frontotemporal degeneration. 5, 6 AS performance is controlled by a well-described frontoparietal cortical network [7] [8] [9] ; normal elderly (NE) with impaired AS performance have impaired EF and subtle structural alterations in this network. 10 Because the AS task is sensitive to presymptomatic neurodegeneration in other diseases, 11 we hypothesized NE with impaired AS performance might have presymptomatic AD or a related disorder.
Individuals with mild cognitive impairment (MCI) have clear cognitive deficits but are able to maintain their function in activities of daily living. 12 A diagnosis of MCI indicates decline in one or more cognitive domains, usually memory, but sometimes including executive dysfunction. 13 The development of executive dysfunction in amnestic MCI is associated with conversion to AD dementia, suggesting that processes reflected by EF may help compensate for other cognitive deficits in the setting of neurodegeneration. 14 We hypothesized that AS performance in MCI would reflect the severity of EF impairment and underlying AD pathology and would be associated with reduced cortical gray matter thickness in brain "AD signature" regions. 15 METHODS Subjects. One hundred eighty-two voluntary subjects (aged 48-86 years; 83 male, 99 female) were evaluated at the University of California, San Francisco (UCSF) Memory and Aging Center. All subjects underwent neurologic examinations, neuropsychological testing, and eye movement measurements. Additionally, most subjects had MRI scans of their brains. Subjects were divided into 3 diagnostic groups based on their neurologic status: cognitively NE (n 5 118), patients with MCI (n 5 36), and patients with AD dementia (n 5 28). APOE e4 genotypes were determined as previously described. 16 Demographic information is shown in table 1.
Standard protocol approvals, registrations, and patient consents. All procedures were approved by the UCSF IRB, and written informed consent was obtained from all participants or using an IRB-approved surrogate consenting procedure (patients with AD).
Diagnoses. NE were required to have no cognitive complaints, a
Mini-Mental State Examination (MMSE) 17 score $27, a Clinical Dementia Rating-Sum of Boxes (CDR-SB) 18 score of zero, and a normal neurologic examination.
Subjects in the MCI group met at least 2 of the following criteria: a subjective cognitive complaint, a CDR-SB score of $0.5, and at least one neuropsychological test score .1.5 SDs below the age-adjusted norm. Overall CDR scores were 0 or 0.5. All subjects with MCI had received their diagnosis before enrollment.
Subjects with AD dementia met the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association probable criteria for AD. 19 All subjects with AD had MMSE scores $12 (range 12-30; median 21) and CDR scores of 0.5 or 1. CDR-SB scores ranged from 2.0 to 9.0.
Eye movement recording and analysis. Subjects were seated with their heads stabilized on a chinrest and shown visual targets (0.1°-0.3°) in a dim room. The movements of the right eye were recorded on a Dual Purkinje Image Eye Tracker (Fourward Technologies, Gallatin, MO) at 1,000 samples/s and low-pass filtered at 330 Hz.
All experiments used custom presentation software (Maestro, UCSF). As shown in figure 1A , the experiment began with a set of visually guided prosaccade trials. Each trial began with a central fixation point for a variable duration (1,000-2,500 milliseconds); eye position was measured for the last 1,000 milliseconds. After a 200-millisecond blank screen (gap), the target then appeared in an eccentric location (5°or 10°horizontally or vertically) and remained visible for 1,000 milliseconds. Subjects were instructed to look at the fixation point until it disappeared, then look at the eccentric target. Data were included for each condition if at least 8 responses were recorded.
Next, a block of AS trials was presented. Each AS trial began with central fixation for 1,000 to 2,500 milliseconds, with eye position recorded for the final 1,000 milliseconds. After a 200-millisecond gap, a target appeared 10°left or right and remained lit for 1,000 milliseconds. Subjects were instructed to look at the target in the center then look in the opposite direction of the visual target, and to correct mistakes if they found themselves looking at the eccentric target. A minimum of 12 responses was required. Subjects verbally confirmed the instructions to demonstrate their understanding of the AS task.
Eye movement data were analyzed interactively offline using custom MATLAB code (MathWorks, Natick, MA). Saccade latencies were computed as the onset of the first eye movement after the eccentric target appeared. AS responses were considered correct if the first eye movement after eccentric target onset had an amplitude greater than 3°in the direction opposite the target, and self-corrected AS errors were defined as AS that occurred within 500 milliseconds of the initial response ( figure 1B ).
Neuropsychological and functional evaluation. All subjects were administered a standardized comprehensive neuropsychological battery. Tests of general cognition and functional abilities included the MMSE and CDR. Neuropsychological tests of EF included a modified trail-making test of set-shifting, 20 trial 1 of the Design Fluency subtest from the Delis-Kaplan Executive Function System, 21 the Stroop Interference condition to test inhibition, 20 the ability to perform 5 arithmetic calculations, and interpretation of 3 similarities and 3 proverbs (abstraction). Language skills were evaluated with the 15-item Boston Naming Test, 22 phonemic fluency (number of D or H words in 1 minute), and category fluency (number of animals or vegetables in 1 minute). Visuospatial abilities were tested using the Number Location condition from the Visual Object Spatial Perception battery 23 and a copy of a simplified version of the Rey-Osterrieth figure. Memory was assessed by a 10-minute recall of the simplified Rey-Osterrieth figure and the longest correct Forward Digit Span. The Functional Activities Questionnaire 24 and Activities of Daily Living-Prevention Instrument 25 were used to assess capacity for daily functioning. For group comparisons, subjects with missing data were excluded from the relevant analysis.
MRI scans. MRI scans were obtained for 121 subjects on 1 of 3 scanners: a 1.5-tesla Magnetom VISION system (Siemens, Inc., Iselin, NJ) at the San Francisco VA Magnetic Resonance Unit (n 5 8), a 3-tesla TIM Trio scanner (Siemens, Inc.) at the UCSF Neuroscience Imaging Center (n 5 104), or a 4-tesla MedSpec system (Bruker AXS, Inc., Madison, WI) also at the San Francisco VA. To control for potential influences of scanner type, we performed our correlation analyses with and without scanner type as a covariate. No differences were seen; results reported here are without the covariate.
Using Freesurfer (version 5.1, http://surfer.nmr.mgh.harvard. edu/), we calculated cortical thickness in 9 regions of interest (ROIs) previously identified as showing cortical thinning in AD 15 ; together, these ROIs form an AD signature. Hippocampal and amygdala structural volumes were also derived from Freesurfer and were normalized by total intracranial volume to control for potential correlation with head size.
Statistical analyses. All analyses were performed using SPSS software (version 19.0; SPSS Inc., Chicago, IL). We compared group performance on neuropsychological tests and oculomotor measures using 1-way analyses of variance with Games-Howell corrections for multiple comparisons with unequal variance or Tukey B for equal variance. Where data were insufficient for one group (subjects with AD), independent t tests were used to compare MCI and NE. For all between-group comparisons, a p value of ,0.05 after post hoc correction for multiple comparisons was considered significant. Bivariate correlations of AS performance with neuropsychological measures were performed within each group to assess the relationship of AS performance to more standard measures of cognitive function. To control for disease severity, in some analyses, correlations were also performed with the CDR-SB as a covariate for the MCI and AD cohorts. For tests of EF, we corrected for multiple comparisons with a Bonferroni correction; 6 neuropsychological tests (table 2) were considered to fall in the EF domain, so significance was evaluated at p 5 0.05/6 5 0.0083. For correlations between AS performance and anatomical structure, we used a hierarchical approach. First, we hypothesized that AS performance was correlated with cortical atrophy within the AD signature regions, and tested this with bivariate correlations for each subject cohort and the study population as a whole. We then investigated which ROIs within the AD signature showed the strongest relationship with AS performance. Oculomotor responses. Patients with AD were slower to initiate eye movements than either patients with MCI or the NE (p , 0.001 for both; figure 2A ). Subjects with AD were also slower to respond during the AS task for both correct (p , 0.001; figure 2B left) and error (p , 0.001 vs NE; p 5 0.078 vs MCI; figure 2B , right panel) responses. Both NE and MCI groups showed a wide range of performance on the AS task, from poor to excellent; surprisingly, the mean percentage of correct responses for the 2 groups was very similar (figure 2C, left panel). The patients with AD had a lower percentage of correct responses than both the NE and MCI groups (p , 0.001). All 3 groups spontaneously corrected error trials during the task, indicating that they understood the instructions. The metric "ASTotal" indicates the total percentage of trials either correctly performed or successfully self-corrected (figure 2C, right panel). Subjects with AD corrected a lower percentage of errors than either the subjects with MCI or the NE (p , 0.001). AS performance and cognitive function. In all subjects combined, the percentage of correct AS responses correlated with a variety of neuropsychological measures, most strongly tests of EF (table 2) . Many of the correlations in MCI and AD groups were likely related to disease severity because controlling for CDR-SB diminished the effects. Overall, the strongest correlation was with the Stroop Inhibition test, even after controlling for CDR-SB and correcting for multiple comparisons. In NE, other measures of EF, including Backward Digit Span, time to complete the modified trails, and abstraction, were also correlated with AS performance. Subjects with MCI showed weak or no correlations with these measures, even controlling for disease severity. The same pattern of results was seen when education was included as a covariate ( . In most AD signature ROIs, subjects with MCI had higher cortical thickness than those with AD. In 2 ROIs, the inferior temporal gyrus and the supramarginal gyrus, cortical thickness was reduced in MCI compared with NE (p , 0.05). We hypothesized that the observed differences in cortical thickness could explain some of the variance in AS task performance. We first examined AD signature across all subjects and found that cortical thickness was correlated with the percentage of correct AS responses (r 5 0.352, p , 0.001; table 3). When we split by diagnostic group, only the subjects with MCI showed a correlation between AD signature and AS percentage correct (r 5 0.499, p , 0.05), although there were trends in both AD and NE. We next examined individual regions within the AD signature composite to investigate whether the effect was driven by differences in regional atrophy. Subjects with MCI showed strong associations between AS performance and cortical thickness in the superior frontal gyrus, the precuneus, and the angular gyrus (table 3) . The same pattern of results held when controlling for disease severity using CDR-SB in the patient cohorts and when we added age and education as covariates. Subjects with AD only showed a strong correlation between AS performance and cortical thickness in the inferior temporal gyrus. There were no correlations between brain atrophy and AS performance in the NE group.
DISCUSSION Surprisingly, performance on the AS task was similar for NE and subjects with MCI. Both groups exhibited a wide range of performance and on average performed better than subjects in the AD cohort. Across subjects, performance on the AS task maintained the expected relationship with other neuropsychological tests of EF, confirming the validity of the AS task as a measure of EF. In all subjects, even after controlling for disease severity, AS performance was strongly correlated with thinning in cortical AD signature regions but not the hippocampus or amygdala. The correlation between AD signature cortical thinning and AS performance was strongest in the subjects with MCI, suggesting that AS performance in this population may reflect the degree of AD pathology within the frontoparietal oculomotor network or in regions influencing network integrity. In the AD dementia group, there was a trend toward a correlation; however, the small sample size and greater cognitive impairment in this group may have limited our ability to evaluate this relationship because of floor effects. Thus, in patients with MCI, the AS task may be useful as a clinical measure of cortical AD burden; in patients with AD dementia, the overall level of impairment may limit the utility of the AS task as a measure.
Our results are consistent with previous studies of AS performance in NE and AD that demonstrated impaired performance in AS that correlated with disease severity and measures of EF. 5, 6, 26 Our results are also similar to a previous study that used a bedside AS to demonstrate that subjects with MCI displayed intermediate levels of impairment between NE and AD. 2 Although we found no difference in the percentage of correct AS trials between NE and MCI in this study, the mean score was numerically lower in MCI. Because the current study included a much larger sample of subjects with MCI with characteristic neuropsychological, functional, and medial temporal lobe atrophy findings (table 1, figure e-1, table e-1), we believe that the subtle differences in results may have arisen from differences in disease severity between the very small MCI group in the previous study and the larger group studied here, or from differences between the bedside AS task and the laboratory AS task used here. Because the bedside AS is performed in a lighted room with more visual distractors than the laboratory AS task, it may be more difficult for individuals with early AD pathology who have impaired attention or inhibitory control.
Our findings also confirm the relationship between cortical thinning in AD signature regions and EF in MCI seen in a previous study. 27 In this patient group, we found that cortical thickness in the superior frontal gyrus ROI was strongly associated with EF as measured by the AS task. This ROI encompasses some of the oculomotor network nodes where AS performance has been correlated with gray matter volume in NE and in patients with AD dementia and frontotemporal degeneration, 5,10 further supporting the hypothesis that alterations in AS performance reflect damage to the frontoparietal network underlying voluntary saccade control and EF.
In the patients with AD, there was a strong correlation between AS performance and cortical thinning in the inferior temporal gyrus but not in other AD signature ROIs. Because the inferior temporal gyrus is not believed to contain oculomotor network nodes, we speculate that this relationship could reflect the AS task's strong correlation with overall disease severity in AD dementia. 5,6 Table 3 Correlations among cortical thickness, medial temporal lobe volume, and antisaccade performance Although a number of NE displayed poor AS performance, it did not correlate with AD signature cortical thinning. Because AD signature cortical thinning is correlated with CSF biomarkers of AD pathology in other studies of NE, 28 these findings suggest that impaired AS performance in NE may have different etiologies than in incipient AD, such as alterations in white matter or age-related changes in dynamic network plasticity, that are also influenced by individuals' genotypes for a variety of synaptic genes expressed within the EF network. 29 Alternatively, cortical thinning in AD signature regions may not be sensitive to the proximal causes of AS dysfunction in healthy elders because of some oculomotor network nodes falling outside of AD signature ROIs. 10 Studies in patients with schizophrenia and their first-degree relatives suggest that AS performance is strongly influenced by genetic factors that predispose to schizophrenia. 30, 31 We hypothesize that such genetic factors might have a stronger influence on AS performance in NE than AD pathology as measured by cortical thinning. This implies that the AS task might be used to assess other biological factors that interact with incipient AD pathology to determine cognitive function particularly in healthy elderly individuals.
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